• Je něco špatně v tomto záznamu ?

Surgical management of pancreatic neuroendocrine tumors - An EYSAC and E-AHPBA international survey of current practice

A. Brandl, D. Lundon, AK. Siriwardena, D. Sochorova, W. Ceelen, M. Besselink, K. Soreide, S. Stättner

. 2024 ; 50 (10) : 108544. [pub] 20240721

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018779

INTRODUCTION: Pancreatic neuroendocrine tumors (pNET) exhibit a wide spectrum of clinical behavior, which makes their assessment and management quite challenging. The purpose of this study was to comprehensively assess the existing treatment landscape for patients with pNET. MATERIALS AND METHODS: The study was conducted with the support of the ESSO-EYSAC Research Academy in collaboration with the E-AHPBA. An online survey was distributed via email and social media to surgical networks across Europe and beyond (September 1-30, 2023). RESULTS: Overall, 155 complete responses were obtained. A specialized NET tumor board was present at the institutions of 94 (61 %) of the study participants. The most frequently applied guidelines were from ENETS (n = 97; 63 %), NCCN (n = 74; 48 %), and ESMO (n = 53; 34 %). For resectability, similar criteria as in pancreatic ductal adenocarcinoma were used by 111 (72 %) participants, even though 116 (75 %) participants believed that pNET/pNEC should have their own resectability criteria. Most respondents used somatostatin analogues (n = 126; 81 %) and chemotherapy (n = 85; 55 %) as neoadjuvant treatments, followed by molecularly targeted agents (n = 45; 29 %) and PRRT (n = 37; 24 %). Only 17 (11 %) participants agreed/strongly agreed that the management of pNET/pNEC is sufficiently addressed in surgical education programs. CONCLUSION: This international survey highlighted areas for improvement in the care of pNET, namely the lack of pNET-specific resectability criteria and educational programs addressing pNET management.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018779
003      
CZ-PrNML
005      
20241024111353.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejso.2024.108544 $2 doi
035    __
$a (PubMed)39059195
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Brandl, Andreas $u Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Germany. Electronic address: andreas.brandl@med.uni-heidelberg.de
245    10
$a Surgical management of pancreatic neuroendocrine tumors - An EYSAC and E-AHPBA international survey of current practice / $c A. Brandl, D. Lundon, AK. Siriwardena, D. Sochorova, W. Ceelen, M. Besselink, K. Soreide, S. Stättner
520    9_
$a INTRODUCTION: Pancreatic neuroendocrine tumors (pNET) exhibit a wide spectrum of clinical behavior, which makes their assessment and management quite challenging. The purpose of this study was to comprehensively assess the existing treatment landscape for patients with pNET. MATERIALS AND METHODS: The study was conducted with the support of the ESSO-EYSAC Research Academy in collaboration with the E-AHPBA. An online survey was distributed via email and social media to surgical networks across Europe and beyond (September 1-30, 2023). RESULTS: Overall, 155 complete responses were obtained. A specialized NET tumor board was present at the institutions of 94 (61 %) of the study participants. The most frequently applied guidelines were from ENETS (n = 97; 63 %), NCCN (n = 74; 48 %), and ESMO (n = 53; 34 %). For resectability, similar criteria as in pancreatic ductal adenocarcinoma were used by 111 (72 %) participants, even though 116 (75 %) participants believed that pNET/pNEC should have their own resectability criteria. Most respondents used somatostatin analogues (n = 126; 81 %) and chemotherapy (n = 85; 55 %) as neoadjuvant treatments, followed by molecularly targeted agents (n = 45; 29 %) and PRRT (n = 37; 24 %). Only 17 (11 %) participants agreed/strongly agreed that the management of pNET/pNEC is sufficiently addressed in surgical education programs. CONCLUSION: This international survey highlighted areas for improvement in the care of pNET, namely the lack of pNET-specific resectability criteria and educational programs addressing pNET management.
650    _2
$a lidé $7 D006801
650    12
$a nádory slinivky břišní $x chirurgie $7 D010190
650    12
$a neuroendokrinní nádory $x chirurgie $7 D018358
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a lékařská praxe - způsoby provádění $x statistika a číselné údaje $7 D010818
650    _2
$a pankreatektomie $7 D010180
650    _2
$a somatostatin $x analogy a deriváty $x terapeutické užití $7 D013004
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lundon, Dara $u Department of Urology, Icahn School of Medicine at Mount Sinai Hospitals, New York, United States
700    1_
$a Siriwardena, Ajith K $u Regional Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Manchester, UK
700    1_
$a Sochorova, Dana $u Department of Surgery, Tomas Bata Regional Hospital, Zlin, Czech Republic
700    1_
$a Ceelen, Wim $u Department of GI Surgery, Ghent University Hospital, and Cancer Research Institute Ghent (CRIG), Belgium
700    1_
$a Besselink, Marc $u Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, the Netherlands
700    1_
$a Soreide, Kjetil $u Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, Stavanger, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway
700    1_
$a Stättner, Stefan $u Department of General, Visceral and Vascular Surgery, Salzkammergutklinikum, Vöcklabruck, Austria
773    0_
$w MED00005360 $t European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology $x 1532-2157 $g Roč. 50, č. 10 (2024), s. 108544
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39059195 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111347 $b ABA008
999    __
$a ok $b bmc $g 2201565 $s 1230752
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 50 $c 10 $d 108544 $e 20240721 $i 1532-2157 $m European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology $n Eur J Surg Oncol $x MED00005360
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace